SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Maurice Winn who wrote (1605)10/28/1998 10:03:00 AM
From: A.J. Mullen  Read Replies (1) of 1762
 
You're right wrt antagonistic. I wasn't using it in the specific biomolecular sense. Also see your point that the once Rituxan is taken, the damage is done, protection may have been conferred, so little lost by adding Y2B8. The treatments are not commutative. If I were the patient with intermediate, I would want to hit the little bastards with the heavy guns of Y2B8 without hardening them first with Rituxan.
Best Wishes - Aj
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News